Glucagen Hypokit (Glucagon)

Glucagen Hypokit is indicated for the rapid treatment of severe hypoglycemia in patients with diabetes when immediate glucose elevation is required.

• Emergency reversal of hypoglycemia when the patient is unconscious, unable to swallow, or experiencing seizures.
• Use in adults and children with type 1 or type 2 diabetes who have taken excess insulin or oral hypoglycemic agents.
• Administration by trained medical personnel, emergency responders, or caregivers in a non‑hospital setting.
• Provides an alternative to oral glucose when intravenous dextrose is not readily available.

The pharmacologic action of glucagon can produce a range of transient effects, most of which are mild and self‑limiting.

Common

• Nausea or vomiting
• Flushing or warmth at the injection site
• Transient headache
• Mild abdominal discomfort

Serious

• Severe allergic reaction (anaphylaxis) with rash, itching, swelling, or difficulty breathing
• Rapid heart rate (tachycardia) or irregular heartbeat
• Marked rise in blood pressure

Before using Glucagen Hypokit, certain safety considerations should be reviewed to minimize risks.

• Verify the patient’s diagnosis of severe hypoglycemia and confirm that oral glucose administration is not feasible.
• Ensure proper reconstitution and correct injection technique according to the kit instructions.
• Store the kit at controlled room temperature; discard after the expiration date or if the solution appears discolored.
• Use with caution in patients with known glucagon allergy or a history of pheochromocytoma.
• Monitor the patient’s blood glucose after administration and provide additional medical care if levels remain low.

Glucagon may interact with other medications, affecting its efficacy or safety profile.

Avoid

• Beta‑blockers, which can blunt the expected rise in blood glucose.
• Long‑acting insulin analogues that may prolong hypoglycemia despite glucagon administration.

Use with caution

• Oral hypoglycemic agents (e.g., sulfonylureas) that may increase the risk of recurrent hypoglycemia after glucagon.
• Catecholamine‑releasing drugs that could exacerbate cardiovascular effects such as tachycardia.
• Anticholinergic medications that may interfere with gastrointestinal motility and affect glucagon absorption.